PolyNovo's business objectives are to tailor the properties of NovoSorbTM for medical devices in strategic markets. We have partnered and intend to partner with medical device companies in most key markets. In a limited number of situations we will build further value in NovoSorbTM based products prior to partnering.
NovoSorbTM technology spans three families of composition of matter patents. Within each class of NovoSorbTM the mechanical performance, rate of degradation and the degradation products can be altered independently to suit the application environment. The typical biological degradation of these polymers shows a long retention of mechanical properties and device structure, followed by controlled but short complete mass loss. The ability to reproducibly manage the degradation process in this way gives NovoSorbTM one of its unique advantages over other biodegradable technologies.
PolyNovo's operations are based in Melbourne, Australia, within the Commonwealth Scientific and Industrial Research Organisation (CSIRO) Molecular and Health Technologies campus. Our location facilitates access to equipment and an ability to collaborate with world-class scientists across multiple healthcare disciplines.
PolyNovo Biomaterials Pty Ltd (PolyNovo) is an operating division of Xceed Biotechnology Ltd, an Australian Stock exchange listed company (ASX Code: XBL)
CSIRO Science Education Centre
Xceed Biotechnology